Document detail
ID

oai:HAL:hal-04149571v1

Topic
HIV prevention HIV treatment Long-acting cART PrEP Quantitative study Long-acting cART HIV treatment Qua... [SDV.SPEE]Life Sciences [q-bio]/Sa...
Author
Slama, Laurence Porcher, Raphael Linard, Françoise Chakvetadze, Catherine Cros, Agnès Carillon, Séverine Gallardo, Lucille Viard, Jean-Paul Molina, Jean-Michel
Langue
en
Editor

HAL CCSD;BioMed Central

Category

sciences: life sciences

Year

2023

listing date

12/15/2023

Keywords
hiv prep prevention study laa treatment
Metrics

Abstract

International audience; BACKGROUND: The use of long acting injectable (LAA) antiretroviral drugs may be an alternative option for HIV treatment and prevention.

Our study focused on patient perspectives to understand which individuals, among people with HIV (PWH) and pre-exposure prophylaxis (PrEP) users, would constitute the preferential target for such treatments in terms of expectations, tolerability, adherence and quality of life.

METHODS: The study consisted in one self-administrated questionnaire.

Data collected included lifestyle issues, medical history, perceived benefits and inconveniences of LAA.

Groups were compared using Wilcoxon rank tests or Fisher’s exact test.

RESULTS: In 2018, 100 PWH and 100 PrEP users were enrolled.

Overall, 74% of PWH and 89% of PrEP users expressed interest for LAA with a significantly higher rate for PrEP users (p = 0.001).

No characteristics were associated with acceptance of LAA in both groups in term of demographics, lifestyle or comorbidities.

CONCLUSION: PWH and PrEP users expressed a high level of interest in LAA, since a large majority seems to be in favor of this new approach.

Further studies should be conducted to better characterize targeted individuals.

Slama, Laurence,Porcher, Raphael,Linard, Françoise,Chakvetadze, Catherine,Cros, Agnès,Carillon, Séverine,Gallardo, Lucille,Viard, Jean-Paul,Molina, Jean-Michel, 2023, Injectable long acting antiretroviral for HIV treatment and prevention: perspectives of potential users, HAL CCSD;BioMed Central

Document

Open

Share

Source

Articles recommended by ES/IODE AI

Gene expression profiles in clinically T1-2N0 ER+HER2− breast cancer patients treated with breast-conserving therapy: their added value in case sentinel lymph node biopsy is not performed
breast cancer sentinel lymph node biopsy gene expression profile adjuvant chemotherapy gep treated status guideline-2020 outcome patients cancer chemotherapy breast predict